Breast Ca Mortality Decline Greatest in Younger ER+ Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70

BETHESDA, Maryland—A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70 (J Clin Oncol published online April 2, 2007). Between 1990 and 2003, breast cancer mortality rates declined by 24%. The researchers found that among women under age 70, mortality declined 38% for those with ER-positive tumors vs 19% for ER-negative tumors, and among women 70 or older, by 14% for ER-positive tumors vs no decline for ER-negative tumors.

"These trends since 1990 are likely attributable to at least two factors: the use of tamoxifen after surgery . . . and widespread use of screening mammography, which is more likely to detect the slow-growing tumors that tend to be ER-positive," said lead author Ismail Jatoi, MD, PhD, of the Uniformed Services University of the Health Sciences.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content